Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
A video roundup of the week’s top industry news stories.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
Contract Pharma Stream offers a centralized destination where users can watch expert-led sessions anytime, anywhere
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
The money will be used to relocate, expand, and modernize existing operations.
October 21, 2026
By: Patrick Lavery
Editor’s Take: Spray drying and HPAPI manufacturing are technologies that support complex small-molecule API development requirements around the globe.
ESTEVE CDMO is investing more than $80 million in China in an effort to strengthen its global manufacturing footprint. The investment is earmarked to relocate—to Shaoxing—expand and modernize existing operations.
The new Shaoxing site will “significantly” expand, according to ESTEVE CDMO, the company’s manufacturing capabilities in Asia. This involves a combination of increased capacity, advanced technologies, and the flexibility to accommodate future growth.
Typically, ESTEVE CDMO offers technologies including spray drying and highly potent API (HPAPI) manufacturing. This supports increasingly complex international requirements of small-molecule API development and manufacturing.
ESTEVE CDMO’s presence in China dates back to the year 2000. In that time, operations in China have come to complement available manufacturing capabilities across Europe, the Americas, and Asia.
In terms of area, the new facility has three manufacturing workshops housing a total reaction volume of 250 cubic meters. On top of that, more than 150 cubic meters are reserved for future development. The simple math—over 400 cubic meters of total reaction volume may be made available as manufacturing needs evolve.
“This investment is an important step in the sustained growth of ESTEVE CDMO[‘s] global manufacturing platform,” President Joan Petit said. “[It] allows us to bring our capabilities closer to customers in Asia while leveraging the expertise of our global network. Our ambition is clear: build a leading global CDMO business with the capabilities and flexibility to support our partners worldwide. This is what drives us: making a difference for patients and contributing to our shared purpose of improving lives together.”
ESTEVE CDMO says the new site achieved a “Very Good” rating from the Building Research Establishment Environmental Assessment Method. This, the company says, speaks to the environmental, health, and safety considerations integrated into the facility’s design and operation.
Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !